Viatris (HAM:VIA) Total Equity: €12,679 Mil (As of Mar. 2026)


HAM:VIA Viatris Inc HAM:VIA
60 GF Score
Price €14.10
GF Value €9.58
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Total Equity?

Viatris HAM:VIA -1.15% 60 Total Equity is €12,679 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.58 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Viatris's total equity for the quarter that ended in Mar. 2026 was €12,679 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Viatris Total Equity Historical Data

* Premium members only.

The historical data trend for Viatris's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Total Equity Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,136.04 19,892.25 18,768.61 17,796.90 12,563.45

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,476.62 13,499.62 12,965.40 12,563.45 12,678.91
HAM:VIA
60GF Score
Viatris Inc HAM:VIA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Viatris's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=31762.907-19199.457
=12,563

Viatris's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=31861.929-19183.018
=12,679

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €12,679 Mil mean?
Viatris (HAM:VIA) has a Total Equity of €12,679 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Viatris and its competitors.
Is Viatris' Total Equity too high?
Viatris' current Total Equity is €12,679 Mil. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Total Equity compare to NBIX and UTHR?
Viatris' Total Equity of €12,679 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Viatris and its competitors. Viatris's current Total Equity is €12,679 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.58, compared to a current price of €14.10 — trading 47.2% above its estimated fair value. The current Total Equity is €12,679 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Total Equity is €12,679 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.10 is trading 47.2% above its estimated GF Value™ of €9.58. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Total Equity: €12,679 Mil
  • GF Value™: €9.58 vs. price of €14.10 (47.2% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for HAM:VIA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.10
Price
€9.58
GF Value